NATCO gets a boost in favourable verdict on Copaxone

Posted By:
Subscribe to GoodReturns

NATCO Pharma has said that the US Court of Appeals for the Federal Circuit ruling, has reversed a district court's finding related to Teva's US Patent for Copaxone.

This would essentially mean that NATCO could launch the generic Copaxone - through its
marketing partner - Mylan Inc., during May 2014, subject to FDA approval. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.

The product is estimated to have clocked revenues, in USA, of about US $3.45 Billion during 2012.

Shares in Natco which closed at Rs 491 on Friday, may receive a boost when markets re-open for trading on Monday.

Read more about: natco
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?